ZBIO
Zenas Biopharma Inc (ZBIO)
Healthcare • NASDAQ • $19.64+1.92%
- Symbol
- ZBIO
- Exchange
- NASDAQ
- Sector
- Healthcare
- Industry
- Biotechnology
- Price
- $19.64
- Daily Change
- +1.92%
- Market Cap
- $1.22B
- Trailing P/E
- N/A
- Forward P/E
- -3.90
- 52W High
- $44.60
- 52W Low
- $8.54
- Analyst Target
- $42.00
- Dividend Yield
- N/A
- Beta
- N/A
Zenas BioPharma, Inc., a clinical-stage biopharma company, engages in the development and commercialization of transformative immunology-based therapies. Its lead product candidate is obexelimab, a bifunctional monoclonal antibody designed to bind CD19 and Fc?RIIb for the treatment of various I&I diseases and various indications, including immunoglobulin G4-related disease, multiple sclerosis, and systemic lupus erythematosus. The company develops ZB002, an anti-TNFa monoclonal antibody; ZB004, a CTLA-4-Ig fusion protein designed to have an extended half-life versus; and ZB001, an anti-IGF-1R monoclonal antibody. The company was formerly known as Zenas BioPharma (Cayman) Limited and changed its name to Zenas BioPharma, Inc. in August 2023. The company was incorporated in 2019 and is headqu…
Company websiteResearch ZBIO on Stk-Ai
Stk-Ai gives you screening across 100+ fundamental metrics, AI-powered analysis, target predictions, backtested signals, and portfolio tracking — all in one place.
Data shown is for informational purposes only and is not investment advice. Prices and metrics may be delayed.